Clinical trials: Restless Legs Syndrome (RLS)
Restless Legs Syndrome
REQUIP RLS Post Marketing Surveillance
post-marketing surveillance to monitor safety and efficacy of ropinirole during using of treatment for RLS
- Trial name
- REQUIP RLS PMS (NCT01327339)
- Testing
- Ropinirole
- Volunteers
- 755 people
- Sponsor
- GlaxoSmithKline
Renal Pelvis Cancer, Restless Legs Syndrome
Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in the Adverse Events…
- Conditions
- Renal Pelvis Cancer, Restless Legs Syndrome, Epilepsy, Neuropathic Pain
- Trial name
- NCT01138124
- Testing
- Gabapentin prescriptions
- Volunteers
- 54,202 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome
A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause
The purpose of this study is to demonstrate the efficacy of rotigotine against placebo in adolescent subjects with idiopathic Restless Legs Syndrome (RLS) over a 12-week maintenance period and to investigate the safety and…
- Trial name
- NCT03728933
- Testing
- Rotigotine 1 milligram/24 hours, Rotigotine 2 milligram/24 hours
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- UCB Biopharma SRL
Restless Legs Syndrome
Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)
Study to determine the pharmacokinetics (PK) of pramipexole (PPX) after administration of a single dose orally (p.o.) in pediatric patients with the diagnosis of RLS
- Trial name
- NCT02231918
- Testing
- MIRAPEX® - low, MIRAPEX® - medium, MIRAPEX® - high
- Volunteers
- 26 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome
Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome
This was a multicenter, open-label, dose-escalation, Phase 2A study with multiple administrations of the rotigotine transdermal system.
- Trial name
- NCT01495793
- Testing
- Rotigotine
- Where
- 12 sites in United States
- Volunteers
- 42 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Restless Legs Syndrome
Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome
The survey is conducted to investigate the safety and efficacy of long-term use of BI-Sifrol Tablets in Restless Legs Syndrome (RLS) patients with or without renal dysfunction in routine medical practice.
- Trial name
- NCT01174459
- Where
- 159 sites in Japan
- Volunteers
- 571 people
- Sponsor
- Boehringer Ingelheim
Restless Legs Syndrome
Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome
This is a Phase 2, multicenter, open-label, single-arm, optimal dose, long-term follow-up study of monotherapy administration of rotigotine transdermal patch in adolescents with Restless Legs Syndrome (RLS).
- Trial name
- NCT01498120
- Testing
- Rotigotine
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Restless Legs Syndrome
A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome
The purpose of this study is to assess the long-term safety, tolerability and the long-term efficacy of rotigotine treatment in adolescents with idiopathic Restless Legs Syndrome (RLS).
- Trial name
- NCT03992196
- Testing
- Rotigotine 1 mg/24 h, Rotigotine 2 mg/24 h, Rotigotine 3 mg/24 h
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- UCB Biopharma SRL
Sleep Disorder, Restless Legs Syndrome
Oral Iron Frequency for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder
The purpose of this research study is to see if the level of serum ferritin differs based on how often oral iron (in the form of ferrous sulfate) is given to children with restless leg syndrome/periodic limb movement disorder.
- Conditions
- Sleep Disorder, Restless Legs Syndrome, Periodic Limb Movement Sleep Disorder, Iron-deficiency
- Trial name
- NCT04610827
- Testing
- Ferrous sulfate
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic